Teratocarcinoma-Derived Growth Factor 1 (TDGF1) antibody

Details for Product No. ABIN540266
Target
Reactivity
94
33
23
Host
Rabbit
68
22
7
2
Clonality
Polyclonal
Conjugate
Un-conjugated
11
10
10
5
4
4
3
2
2
2
2
2
2
2
2
2
2
Application
Flow Cytometry (FACS), Western Blotting (WB)
50
41
35
26
9
4
4
4
2
2
1
Options
Purpose Rabbit polyclonal antibody raised against synthetic peptide of TDGF1.
Immunogen A synthetic peptide corresponding to amino acids 100-150 of human TDGF1.
Specificity This antibody is specific to cripto.
Target
Alternative Name TDGF1 / CRIPTO (TDGF1 Antibody Abstract)
Pathways EGFR Signaling Pathway
Application Notes Flow Cytometry (1:50)
Western Blot (1:500-1:2000)
The optimal working dilution should be determined by the end user.
Restrictions For Research Use only
Format Liquid
Buffer In Tris-glycine, 150 mM NaCl (0.05 % sodium azide)
Storage 4 °C
Storage Comment Store at 4°C. Do not freeze.
Images
Image no. 1 for anti-Teratocarcinoma-Derived Growth Factor 1 (TDGF1) antibody (ABIN540266) Western blot analysis of TDGF1 in 20 ug of MDA-MB-21 lysate with TDGF1 polyclonal ant...
Product cited in: Xing, Hu, Pietersz, Hosick, McKenzie: "Cripto: a novel target for antibody-based cancer immunotherapy." in: Cancer research, Vol. 64, Issue 11, pp. 4018-23, 2004 (PubMed).

Adamson, Minchiotti, Salomon: "Cripto: a tumor growth factor and more." in: Journal of cellular physiology, Vol. 190, Issue 3, pp. 267-78, 2002 (PubMed).

Schiffer, Foley, Kaffashan, Hronowski, Zichittella, Yeo, Miatkowski, Adkins, Damon, Whitman, Salomon, Sanicola, Williams: "Fucosylation of Cripto is required for its ability to facilitate nodal signaling." in: The Journal of biological chemistry, Vol. 276, Issue 41, pp. 37769-78, 2001 (PubMed).